Athena M. Countouriotis
2016
In 2016, Athena M. Countouriotis earned a total compensation of $1.9M as Senior Vice President and Chief Medical Officer at Halozyme Therapeutics, a 31% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $200,000 |
|---|---|
| Option Awards | $600,012 |
| Salary | $443,000 |
| Stock Awards | $600,002 |
| Other | $8,657 |
| Total | $1,851,671 |
Countouriotis received $600K in option awards, accounting for 32% of the total pay in 2016.
Countouriotis also received $200K in non-equity incentive plan, $443K in salary, $600K in stock awards and $8.7K in other compensation.
Rankings
In 2016, Athena M. Countouriotis' compensation ranked 5,242nd out of 14,075 executives tracked by ExecPay. In other words, Countouriotis earned more than 62.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,242 out of 14,075 | 63rd |
Division Manufacturing | 1,886 out of 5,486 | 66th |
Major group Chemicals And Allied Products | 598 out of 1,900 | 69th |
Industry group Drugs | 446 out of 1,543 | 71st |
Industry Biological Products, Except Diagnostic Substances | 78 out of 287 | 73rd |
Source: SEC filing on March 24, 2017.
Countouriotis' colleagues
We found four more compensation records of executives who worked with Athena M. Countouriotis at Halozyme Therapeutics in 2016.